Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF18A | Q8NI77 | 15/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25096582 | 1.00 | KIF18A (0.35) | KIF18ASCN10AIRAK4FGFR3 | |
| SCHEMBL25096535 | 0.96 | ROCK1 (0.35) | KIF18ASCN10AIRAK4FGFR3 | |
| SCHEMBL25096360 | 0.91 | ROCK2 (0.36) | KIF18ASCN10AIRAK4FGFR3 | |
| SCHEMBL30217685 | 0.91 | ROCK2 (0.36) | KIF18ASCN10AIRAK4FGFR3 | |
| SCHEMBL25096907 | 0.90 | LCK (0.34) | SCN10AIRAK4FGFR3 | |
| SCHEMBL25096348 | 0.89 | FGFR3 (0.39) | FGFR3 | |
| SCHEMBL25096689 | 0.89 | HTR1A (0.37) | KIF18ASCN10A | |
| SCHEMBL25095792 | 0.88 | KIF18A (0.33) | KIF18ASCN10A | |
| SCHEMBL25096717 | 0.88 | PRNP (0.42) | FGFR3 | |
| SCHEMBL25096797 | 0.87 | IRAK4 (0.37) | SCN10AIRAK4FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409536-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2024-12-12 | — | — | US | disclosed |
| EP-4395891-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-118234724-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2023034811-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409536-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | KIF18A 4251/4885SCN10A 3040/4885IRAK4 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.